DrugRepV Browse Page

DrugRepV browse page allows user to take a glance of the particular antiviral agent.Fields in the webpage is hylerlinked ot various external repositories like DrugBank, PubChem, Clinicaltrials.gov,and PubMed.User can explore the biological, Clinical, Chemical, and Structural details of every repurposed drug candidate.By clicking on the table header arrows, user can sort entries in ascending or descending order.


Total number of Records for Antiinfectives For Systemic Use are 889

DrugRepV_ID	Antiviral Name	Drug type	Primary Indication	Secondary Indication	Strain	Pathways	Assay	Activity	Clinical Status	References
DrugRepV_0020	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	GZ01, a recent Asian lineage	NA	Plaque assay	Increase (120 %)	Approved	29033372
DrugRepV_0046	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (50 %)	Approved	28912011
DrugRepV_0047	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28912011
DrugRepV_0048	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	Decrease (50 %)	Approved	28912011
DrugRepV_0049	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	28912011
DrugRepV_0050	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0051	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0052	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0053	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Cytopathic effect (CPE) assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0054	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0055	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	ZIKVNL00013	NA	Plaque assay	No significant effect (0 %)	Approved	28912011
DrugRepV_0202	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0203	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0204	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Ebola virus	VLP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational, Vet approved	27890675
DrugRepV_0209	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved, Investigational, Vet approved	27890675
DrugRepV_0211	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Ebola virus	EBOLA/Mayinga-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27890675
DrugRepV_0221	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.12 ± 0.27 Ct)	Approved	27801778
DrugRepV_0222	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?7.91 ± 2.67 Ct)	Approved	27801778
DrugRepV_0223	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?0.43 ± 3.87 Ct)	Approved	27801778
DrugRepV_0224	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.52 ± 1.27 Ct)	Approved	27801778
DrugRepV_0225	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?2.87 ± 0.22 Ct)	Approved, Investigational	27801778
DrugRepV_0226	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.93 ± 0.25 Ct)	Approved, Investigational	27801778
DrugRepV_0227	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?1.54 ± 3.26 Ct)	Approved	27801778
DrugRepV_0228	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.95 ± 2.69 Ct)	Approved	27801778
DrugRepV_0229	Entecavir	Antiinfectives For Systemic Use	Hepatitis B virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?3.08 ± 0.20 Ct)	Approved	27801778
DrugRepV_0230	Entecavir	Antiinfectives For Systemic Use	Hepatitis B virus	Ebola virus	ME718-1976/Yambuku-Ecran	NA	Real-time PCR	Increase (?4.44 ± 1.11 Ct)	Approved	27801778
DrugRepV_0270	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/New Jersey/15/2007		Relative fluorescent unit	Decrease (50 %)	Approved, Investigational	26833677
DrugRepV_0271	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands/026/2008		Relative fluorescent unit	Decrease (50 %)	Approved, Investigational	26833677
DrugRepV_0272	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands /049/2008		Relative fluorescent unit	No significant effect (50 %)	Approved, Investigational	26833677
DrugRepV_0273	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Brisbane/59/2007		Relative fluorescent unit	No significant effect (50 %)	Approved, Investigational	26833677
DrugRepV_0274	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/New Jersey/15/2007		Plaque assay	Decrease (10 %)	Approved, Investigational	26833677
DrugRepV_0275	Nalidixic Acid	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Brisbane/59/2007		Plaque assay	No significant effect	Approved, Investigational	26833677
DrugRepV_0286	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/New Jersey/15/2007		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0287	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands/026/2008		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0288	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Netherlands /049/2008		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0289	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Influenza virus	A/Brisbane /56/2007		Relative fluorescent unit	Decrease (50 %)	Approved	26833677
DrugRepV_0290	Kaletra	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Real-time PCR	Decrease (1.06 Log10 Copies/GAPDH)	Approved, Investigational	26198719
DrugRepV_0291	Kaletra	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Immunohistochemical assay	Decrease (>90 %)	Approved, Investigational	26198719
DrugRepV_0321	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0322	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOV-eGFP	NA	Immunoflourescence assay	Decrease (50 %)	Approved	27622822
DrugRepV_0342	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0343	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire glycoprotein pseudotype vesicular stomatitis virus	NA	Renilla luciferase assay	Decrease (50 %)	Approved	27622822
DrugRepV_0353	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	Increase	Approved	27622822
DrugRepV_0354	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0364	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0365	Chlortetracycline	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Zaire	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0366	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Ebola Mayinga	NA	Survival assay	No significant effect	Approved	27622822
DrugRepV_0374	Cilastatin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0384	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational	26041706
DrugRepV_0431	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0445	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0458	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0472	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	eGFP-EBOV	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26041706
DrugRepV_0487	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0502	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOV-VLP	NA	Flow cytometry	Decrease (>90 %)	Approved	26041706
DrugRepV_0534	Azithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0537	Clarithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0556	Spiramycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved	26038505
DrugRepV_0565	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Ebola virus	EBOVBlaVP40	NA	Fluorescence-based assay	Decrease (50 %)	Approved, Investigational, Vet approved	26038505
DrugRepV_0580	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Influenza virus	Anhui01		Plaque assay	Decrease (1.3 Log10 copies)	Approved, Investigational	24496798
DrugRepV_0615	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	No significant effect (0 %)	Approved	23577127
DrugRepV_0616	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Lassa virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (60 %)	Approved	23577127
DrugRepV_0635	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Lassa virus	Josiah	NA	Real-time PCR	No significant effect	Approved	23577127
DrugRepV_0636	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Lassa virus	Josiah	NA	Real-time PCR	No significant effect	Approved	23577127
DrugRepV_0654	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (91 %)	Approved	23577127
DrugRepV_0655	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Marburg virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (98 %)	Approved	23577127
DrugRepV_0678	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (99 %)	Approved	23577127
DrugRepV_0679	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	GP derived Pseudovirus	NA	Luciferase reporter assay	Decrease (96 %)	Approved	23577127
DrugRepV_0700	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0701	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	EBOLA-eGFP	NA	Fluorescence-based assay	No significant effect	Approved	23577127
DrugRepV_0727	Dirithromycin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0728	Erythromycin ethylsuccinate	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	ma-EBOV	NA	NA	No significant effect	Approved	23577127
DrugRepV_0760	Clofazimine	Antiinfectives For Systemic Use	Lepromatous leprosy	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (99.665 %)	Approved	27476412
DrugRepV_0782	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (89.915 %)	Approved	27476412
DrugRepV_0785	Micafungin	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (86.88 %)	Approved, Investigational	27476412
DrugRepV_0803	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (61.34 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0839	Isoniazid	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.29 %)	Approved, Investigational	27476412
DrugRepV_0843	Penicillin G Potassium	Antiinfectives For Systemic Use	Septicemia | Meningitis | Pericarditis | Endocarditis | Pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.15 %)	Approved	27476412
DrugRepV_0846	Cefuroxime Axetil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.5 %)	Approved	27476412
DrugRepV_0852	Linezolid	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.395 %)	Approved, Investigational	27476412
DrugRepV_0856	Lincomycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (58.795 %)	Approved, Vet approved	27476412
DrugRepV_0859	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.53 %)	Approved	27476412
DrugRepV_0870	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.1 %)	Approved	27476412
DrugRepV_0876	Norfloxacin	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.51 %)	Approved	27476412
DrugRepV_0878	Amphotericin B	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.04 %)	Approved	27476412
DrugRepV_0886	Ketoconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (60.415 %)	Approved, Investigational	27476412
DrugRepV_0888	Ceftibuten	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.895 %)	Approved	27476412
DrugRepV_0901	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (57.92 %)	Approved	27476412
DrugRepV_0907	Ofloxacin	Antiinfectives For Systemic Use	Respiratory tract infections | Kidney infection | Skin infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.695 %)	Approved	27476412
DrugRepV_0909	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.495 %)	Approved	27476412
DrugRepV_0923	Amikacin Disulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.975 %)	Approved	27476412
DrugRepV_0924	Ciprofloxacin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.87 %)	Approved	27476412
DrugRepV_0926	Spectinomycin Hydrochloride Pentahydrate	Antiinfectives For Systemic Use	Bacterial infections (Gonorrheal urethritis and proctitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.825 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_0937	Penicillin V Potassium	Antiinfectives For Systemic Use	Mild to moderately severe infections due to penicillin G­-sensitive microorganisms	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.165 %)	Approved	27476412
DrugRepV_0938	Ceftriaxone Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55.04 %)	Approved	27476412
DrugRepV_0963	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.235 %)	Approved	27476412
DrugRepV_0968	Ethionamide	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.99 %)	Approved	27476412
DrugRepV_0974	Oxacillin Sodium salt Monohydrate	Antiinfectives For Systemic Use	Staphylococci infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.525 %)	Approved, Investigational	27476412
DrugRepV_0982	Cefixime	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.925 %)	Approved	27476412
DrugRepV_0986	Pyrazinamide	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.975 %)	Approved, Investigational	27476412
DrugRepV_1001	Delavirdine Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.035 %)	Approved	27476412
DrugRepV_1012	Cefaclor	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.11 %)	Approved	27476412
DrugRepV_1015	Chloramphenicol	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.08 %)	Approved	27476412
DrugRepV_1020	Cidofovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.06 %)	Approved	27476412
DrugRepV_1021	Levofloxacin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (Conjunctivitis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.885 %)	Approved	27476412
DrugRepV_1022	Demeclocycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50.41 %)	Approved	27476412
DrugRepV_1026	Cefuroxime Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.005 %)	Approved	27476412
DrugRepV_1029	Ethambutol Dihydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.32 %)	Approved	27476412
DrugRepV_1035	Doxycycline Monohydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.935 %)	Approved	27476412
DrugRepV_1043	Voriconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.235 %)	Approved	27476412
DrugRepV_1045	Dapsone	Antiinfectives For Systemic Use	Leprosy and dermatitis herpetiformis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.585 %)	Approved	27476412
DrugRepV_1053	Bacitracin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.205 %)	Approved	27476412
DrugRepV_1055	Ceftizoxim Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.58 %)	Approved	27476412
DrugRepV_1075	Cefotaxime Acid	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (54.85 %)	Approved	27476412
DrugRepV_1076	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (55 %)	Approved	27476412
DrugRepV_1078	Clindamycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.415 %)	Approved	27476412
DrugRepV_1084	Gemifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Chronic bronchitis and mild-to-moderate pneumonia)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.92 %)	Approved, Investigational	27476412
DrugRepV_1085	Adefovir dipivoxil	Antiinfectives For Systemic Use	Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.3 %)	Approved	27476412
DrugRepV_1090	Cefprozil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.765 %)	Approved	27476412
DrugRepV_1095	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.065 %)	Approved	27476412
DrugRepV_1096	Cefdinir	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.845 %)	Approved	27476412
DrugRepV_1103	Cycloserine	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.77 %)	Approved	27476412
DrugRepV_1109	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.855 %)	Approved, Investigational	27476412
DrugRepV_1111	Moxifloxacin Hydrochloride	Antiinfectives For Systemic Use	Sinusitis | Pneumonia | Chronic bronchitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (53.71 %)	Approved, Investigational	27476412
DrugRepV_1113	Oxytetracycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.71 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1116	Valganciclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.32 %)	Approved	27476412
DrugRepV_1118	4-Aminosalicylic Acid	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (51.44 %)	Approved	27476412
DrugRepV_1131	Methenamine Hippurate	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.645 %)	Approved, Vet approved	27476412
DrugRepV_1132	Cloxacillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.82 %)	Approved	27476412
DrugRepV_1148	Piperacillin	Antiinfectives For Systemic Use	Polymicrobial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.9 %)	Approved	27476412
DrugRepV_1151	Famciclovir	Antiinfectives For Systemic Use	Herpes simplex virus | Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.62 %)	Approved, Investigational	27476412
DrugRepV_1157	Amoxicillin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.335 %)	Approved	27476412
DrugRepV_1163	Sulfanilamide	Antiinfectives For Systemic Use	Vulvovaginitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.175 %)	Approved	27476412
DrugRepV_1165	Rifampin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.505 %)	Approved	27476412
DrugRepV_1167	Cefepime Hydrochloride Hydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (52.89 %)	Approved	27476412
DrugRepV_1177	Doripenem	Antiinfectives For Systemic Use	Intra-abdominal infections and complicated urinary tract infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.47 %)	Approved	27476412
DrugRepV_1187	Cefadroxil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.15 %)	Approved	27476412
DrugRepV_1189	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.03 %)	Approved	27476412
DrugRepV_1191	Dicloxacillin Sodium Salt Monohydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.765 %)	Approved	27476412
DrugRepV_1196	Ganciclovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.48 %)	Approved, Investigational	27476412
DrugRepV_1209	Maraviroc	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.18 %)	Approved, Investigational	27476412
DrugRepV_1212	Zalcitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.06 %)	Approved	27476412
DrugRepV_1216	Kanamycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.43 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1225	Nevirapine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.07 %)	Approved	27476412
DrugRepV_1227	Darunavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.605 %)	Approved	27476412
DrugRepV_1234	Cefotetan Disodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.645 %)	Approved	27476412
DrugRepV_1235	Aztreonam	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.05 %)	Approved	27476412
DrugRepV_1238	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.75 %)	Approved, Investigational	27476412
DrugRepV_1247	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.405 %)	Approved, Investigational	27476412
DrugRepV_1261	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.915 %)	Approved, Investigational	27476412
DrugRepV_1262	Cefditoren Pivoxil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.4 %)	Approved	27476412
DrugRepV_1264	Cefpodoxime Proxetil	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.81 %)	Approved	27476412
DrugRepV_1271	Meropenem	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.025 %)	Approved, Investigational	27476412
DrugRepV_1274	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.2 %)	Approved, Investigational	27476412
DrugRepV_1276	Tigecycline	Antiinfectives For Systemic Use	Complicated skin and skin structure infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.4 %)	Approved	27476412
DrugRepV_1281	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.09 %)	Approved	27476412
DrugRepV_1282	Fosfomycin Calcium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.385 %)	Approved	27476412
DrugRepV_1288	Trimethoprim	Antiinfectives For Systemic Use	Urinary tract infections | Uncomplicated pyelonephritis (with sulfamethoxazole) | Mild acute prostatitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.69 %)	Approved	27476412
DrugRepV_1295	Cilastatin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.065 %)	Approved	27476412
DrugRepV_1302	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.29 %)	Approved, Investigational	27476412
DrugRepV_1307	Neomycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.33 %)	Approved	27476412
DrugRepV_1309	Nafcillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.57 %)	Approved, Investigational	27476412
DrugRepV_1310	Capreomycin Disulfate	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.425 %)	Approved	27476412
DrugRepV_1321	Sulfamethoxazole	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.87 %)	Approved	27476412
DrugRepV_1325	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (49.51 %)	Approved	27476412
DrugRepV_1326	Sulfadiazine	Antiinfectives For Systemic Use	Rheumatic fever | Meningococcal meningitis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (48.975 %)	Approved, Investigational, Vet approved	27476412
DrugRepV_1340	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (47.185 %)	Approved, Investigational	27476412
DrugRepV_1352	Gatifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, sinusitis, Community-acquired pneumonia, and Skin infections)	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.98 %)	Approved, Investigational	27476412
DrugRepV_1362	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.965 %)	Approved	27476412
DrugRepV_1364	Telbivudine	Antiinfectives For Systemic Use	Hepatitis B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.765 %)	Approved	27476412
DrugRepV_1369	Fluconazole	Antiinfectives For Systemic Use	Fungal infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.98 %)	Approved, Investigational	27476412
DrugRepV_1371	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.07 %)	Approved	27476412
DrugRepV_1380	Ampicillin Trihydrate	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (46.895 %)	Approved	27476412
DrugRepV_1382	Foscarnet Sodium	Antiinfectives For Systemic Use	Cytomegalovirus retinitis | Herpesviruses | Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.945 %)	Approved	27476412
DrugRepV_1391	Nitrofurantoin	Antiinfectives For Systemic Use	Urinary tract infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.26 %)	Approved	27476412
DrugRepV_1392	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (45.76 %)	Approved	27476412
DrugRepV_1416	Rifapentine	Antiinfectives For Systemic Use	Tuberculosis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (41.79 %)	Approved, Investigational	27476412
DrugRepV_1433	Idoxuridine	Antiinfectives For Systemic Use	Keratoconjunctivitis and Keratitis caused by herpes simplex virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.78 %)	Approved, Investigational	27476412
DrugRepV_1444	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (43.21 %)	Approved	27476412
DrugRepV_1450	Valacyclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.35 %)	Approved	27476412
DrugRepV_1454	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (40.17 %)	Approved	27476412
DrugRepV_1457	Imipenem	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.8 %)	Approved	27476412
DrugRepV_1460	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (42.985 %)	Approved	27476412
DrugRepV_1478	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (38.68 %)	Approved	27476412
DrugRepV_1482	Rifabutin	Antiinfectives For Systemic Use	Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (35.56 %)	Approved, Investigational	27476412
DrugRepV_1486	Oseltamivir Phosphate	Antiinfectives For Systemic Use	Influenza A/B virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (44.305 %)	Approved	27476412
DrugRepV_1501	Rimantadine Hydrochloride	Antiinfectives For Systemic Use	Influenza A virus	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (39.755 %)	Approved, Investigational	27476412
DrugRepV_1516	Saquinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (32.635 %)	Approved, Investigational	27476412
DrugRepV_1517	Telithromycin	Antiinfectives For Systemic Use	Pneumococcal infection | Acute sinusitis | Acute bacterial tonsillitis | Acute bronchitis and bronchiolitis | Lower respiratory tract infection and lobar (pneumococcal) pneumonia	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (31.37 %)	Approved	27476412
DrugRepV_1522	Streptomycin Sulfate	Antiinfectives For Systemic Use	Tuberculosis | Tularemia | Plague | Brucellosis | Endocarditis	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (28.56 %)	Approved, Vet approved	27476412
DrugRepV_1530	Clindamycin Palmitate Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (22.29 %)	Approved	27476412
DrugRepV_1534	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Flow cytometry	Decrease (50 %)	Approved	27476412
DrugRepV_1541	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Flow cytometry	No significant effect (50 %)	Approved	27476412
DrugRepV_1545	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Flow cytometry	Increase (120 %)	Approved	27476412
DrugRepV_1550	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	DAK_41525	NA	Flow cytometry	No significant effect	Approved	27476412
DrugRepV_1557	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Zika virus	MEX_I_7	NA	Fluorescence-based assay	Decrease (50 %)	Approved	27476412
DrugRepV_1576	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Rift Valley fever virus	MP12-Luc	NA	Luciferase reporter assay	Decrease (74 %)	Approved, Investigational	26217313
DrugRepV_1592	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4 Logs reduction)	Approved	26217313
DrugRepV_1594	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4.5 Logs reduction)	Approved	26217313
DrugRepV_1596	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (1 Logs reduction)	Approved	26217313
DrugRepV_1598	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (3 Logs reduction)	Approved	26217313
DrugRepV_1600	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (4 Logs reduction)	Approved	26217313
DrugRepV_1602	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (6 Logs reduction)	Approved	26217313
DrugRepV_1604	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (2 Logs reduction)	Approved	26217313
DrugRepV_1606	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (5 Logs reduction)	Approved	26217313
DrugRepV_1608	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	rMP12	NA	Plaque assay	Decrease (100 %)	Approved	26217313
DrugRepV_1622	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Influenza virus	A/Anhui/01/2013		Transcriptomic response-DEG	Decrease	Approved, Investigational	24991006
DrugRepV_1930	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Plaque assay	Decrease (2 Logs)	Approved	28814523
DrugRepV_1935	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Real-time PCR	Decrease (0 %)	Approved	28814523
DrugRepV_1940	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	H/PF/2013	NA	Immunoflourescence assay	Decrease	Approved	28814523
DrugRepV_2015	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2030	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (90 %)	Approved	26585243
DrugRepV_2031	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (50 %)	Approved	26585243
DrugRepV_2032	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (87.5 %)	Approved	26585243
DrugRepV_2033	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	Decrease (95 %)	Approved	26585243
DrugRepV_2034	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	Zaire strain-pEBOV	NA	Firefly luciferase assay	No significant effect (0 %)	Approved	26585243
DrugRepV_2038	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Cell viability assay	Decrease (50 %)	Approved	24841269
DrugRepV_2042	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	Cell viability assay	Decrease (50 %)	Approved	24841269
DrugRepV_2046	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	229E-GFP	NA	Cell viability assay	Decrease (50 %)	Approved	24841269
DrugRepV_2052	Rifabutin	Antiinfectives For Systemic Use	Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Cell viability assay	No significant decrease (10 %)	Approved, Investigational	24841269
DrugRepV_2053	Rifapentine	Antiinfectives For Systemic Use	Tuberculosis	Middle East respiratory syndrome coronavirus	EMC/2012	NA	Cell viability assay	Decrease (50 %)	Approved, Investigational	24841269
DrugRepV_2113	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2114	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2115	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2116	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2117	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2118	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Plaque assay	Decrease (50 %)	Approved	27902933
DrugRepV_2119	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Real-time PCR	Decrease (>1 Log10 (GE/ml))	Approved	27902933
DrugRepV_2120	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	PRVABC-59	NA	Real-time PCR	Decrease (2 Log10 (GE/ml))	Approved	27902933
DrugRepV_2121	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Real-time PCR	Decrease (>1 Log10 (GE/ml))	Approved	27902933
DrugRepV_2122	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Real-time PCR	Decrease (2 Log10 (GE/ml))	Approved	27902933
DrugRepV_2123	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Real-time PCR	Decrease (>1 Log10 (GE/ml))	Approved	27902933
DrugRepV_2124	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar	NA	Real-time PCR	Decrease (>2 Log10 (GE/ml))	Approved	27902933
DrugRepV_2125	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Flow cytometry	Decrease (50 %)	Approved	27902933
DrugRepV_2126	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Paraiba	NA	Flow cytometry	Decrease (50 %)	Approved	27902933
DrugRepV_2127	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	Dakar/41519	NA	Survival assay	Increase	Approved	27902933
DrugRepV_2128	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27163257
DrugRepV_2129	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR766	NA	Virus yield reduction assay	Decrease (50 %)	Approved	27163257
DrugRepV_2198	Neomycin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (10.0220837 %)	Approved	27742486
DrugRepV_2200	Rifampin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (9.11795232 %)	Approved	27742486
DrugRepV_2201	Atazanavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (8.91119067 %)	Approved	27742486
DrugRepV_2210	Pefloxacin Mesylate	Antiinfectives For Systemic Use	Gonococcal urethritis in males	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.83586814 %)	Approved	27742486
DrugRepV_2214	Moroxydine	Antiinfectives For Systemic Use	Influenza	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (7.65475751 %)	Experimental	27742486
DrugRepV_2231	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.95397975 %)	Approved	27742486
DrugRepV_2240	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.35827197 %)	Approved, Investigational	27742486
DrugRepV_2245	Methenamine	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.11366498 %)	Approved, Vet approved	27742486
DrugRepV_2246	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (6.11366498 %)	Approved	27742486
DrugRepV_2258	Biapenem	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.72083061 %)	Investigational	27742486
DrugRepV_2263	Idoxuridine	Antiinfectives For Systemic Use	Keratoconjunctivitis and Keratitis caused by herpes simplex virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.28034643 %)	Approved, Investigational	27742486
DrugRepV_2265	Clindamycin Phosphate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.23907349 %)	Approved	27742486
DrugRepV_2269	Tigecycline	Antiinfectives For Systemic Use	Complicated skin and skin structure infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (5.03969688 %)	Approved	27742486
DrugRepV_2282	Doripenem Hydrate	Antiinfectives For Systemic Use	Intra-abdominal infections and complicated urinary tract infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.71564204 %)	Approved	27742486
DrugRepV_2283	Sulfamethazine	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.70881807 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2299	Sulfapyridine	Antiinfectives For Systemic Use	Dermatitis herpetiformis | Benign mucous membrane pemphigoid | Pyoderma gangrenosum	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.40977237 %)	Approved	27742486
DrugRepV_2301	Thiamphenicol	Antiinfectives For Systemic Use	Infectious diseases in cattle, pigs and poultry)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.40312446 %)	Experimental, Investigational	27742486
DrugRepV_2310	Sulfamethizole	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (4.08218845 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2313	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.98622242 %)	Approved, Investigational	27742486
DrugRepV_2314	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.96247894 %)	Approved	27742486
DrugRepV_2324	Isoniazid	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.74356574 %)	Approved, Investigational	27742486
DrugRepV_2328	Ketoconazole	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.68563359 %)	Approved, Investigational	27742486
DrugRepV_2338	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.43393568 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2343	Protionamide	Antiinfectives For Systemic Use	MDR-TB | Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.29332873 %)	Approved, Investigational	27742486
DrugRepV_2347	Amoxicillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.26461637 %)	Approved	27742486
DrugRepV_2354	Cephradine	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (3.17042436 %)	Approved	27742486
DrugRepV_2358	Sitafloxacin Hydrate	Antiinfectives For Systemic Use	Bacterial infections (respiratory and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.96036077 %)	Experimental, Investigational	27742486
DrugRepV_2360	Enoxacin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.93176568 %)	Approved	27742486
DrugRepV_2368	Ampicillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.75763916 %)	Approved	27742486
DrugRepV_2383	Bacitracin Zinc	Antiinfectives For Systemic Use	Pneumonia and empyema	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.42855269 %)	Approved	27742486
DrugRepV_2403	Clindamycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.19411786 %)	Approved	27742486
DrugRepV_2404	Spectinomycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (Gonorrheal urethritis and proctitis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (2.18634054 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2424	Sulfameter	Antiinfectives For Systemic Use	Leprosy | Urinary | Respiratory tract infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.81863222 %)	Approved	27742486
DrugRepV_2426	Norfloxacin	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.69457675 %)	Approved	27742486
DrugRepV_2438	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.43192971 %)	Approved, Investigational	27742486
DrugRepV_2439	Rifapentine	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.3653391 %)	Approved, Investigational	27742486
DrugRepV_2445	Gatifloxacin	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, sinusitis, Community-acquired pneumonia, and Skin infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.22310404 %)	Approved, Investigational	27742486
DrugRepV_2447	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.14736269 %)	Approved	27742486
DrugRepV_2448	Cefoperazone	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.13001149 %)	Approved	27742486
DrugRepV_2449	Tetracycline Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (1.08422039 %)	Approved, Vet approved	27742486
DrugRepV_2455	Sulphadimethoxine	Antiinfectives For Systemic Use	Respiratory infection | Urinary tract infection | Enteric infection | Soft tissue infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.99278461 %)	Approved, Vet approved	27742486
DrugRepV_2457	Amikacin Hydrate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.87227544 %)	Approved	27742486
DrugRepV_2459	Pyrazinamide	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.85917346 %)	Approved, Investigational	27742486
DrugRepV_2476	Ethionamide	Antiinfectives For Systemic Use	Tuberculosis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.45109184 %)	Approved	27742486
DrugRepV_2478	Streptomycin Sulfate	Antiinfectives For Systemic Use	Tuberculosis | Tularemia | Plague | Brucellosis | Endocarditis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.42772783 %)	Approved, Vet approved	27742486
DrugRepV_2486	Cefditoren Pivoxil	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	No significant decrease (0.31336219 %)	Approved	27742486
DrugRepV_2510	Maraviroc	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.0137712 %)	Approved, Investigational	27742486
DrugRepV_2511	Carbenicillin Disodium	Antiinfectives For Systemic Use	Urinary tract infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.0151285 %)	Approved	27742486
DrugRepV_2517	Clarithromycin	Antiinfectives For Systemic Use	Microbial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.1486584 %)	Approved	27742486
DrugRepV_2518	Ganciclovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.183847 %)	Approved, Investigational	27742486
DrugRepV_2530	Moxifloxacin Hydrochloride	Antiinfectives For Systemic Use	Sinusitis | Pneumonia | Chronic bronchitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5365847 %)	Approved, Investigational	27742486
DrugRepV_2531	Meropenem	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.5411877 %)	Approved, Investigational	27742486
DrugRepV_2540	Valacyclovir Hydrochloride	Antiinfectives For Systemic Use	Herpes simplex and Zoster virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.6677761 %)	Approved	27742486
DrugRepV_2543	Cefaclor	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.7251215 %)	Approved	27742486
DrugRepV_2546	Ciprofloxacin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.8107955 %)	Approved	27742486
DrugRepV_2554	Oxytetracycline dihydrate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.9136131 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2557	Aztreonam	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-0.9905633 %)	Approved	27742486
DrugRepV_2566	Lincomycin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.1874718 %)	Approved, Vet approved	27742486
DrugRepV_2568	Oxacillin Sodium Monohydrate	Antiinfectives For Systemic Use	Staphylococci infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2220202 %)	Approved, Investigational	27742486
DrugRepV_2569	Entecavir Hydrate	Antiinfectives For Systemic Use	Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2373625 %)	Approved	27742486
DrugRepV_2575	Amprenavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.2615469 %)	Approved	27742486
DrugRepV_2584	Flumequine	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.3882128 %)	Withdrawn	27742486
DrugRepV_2598	Telbivudine	Antiinfectives For Systemic Use	Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.5369604 %)	Approved	27742486
DrugRepV_2606	Lomefloxacin Hydrochloride	Antiinfectives For Systemic Use	Bacterial infections (respiratory tract (chronic bronchitis) and urinary tract)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6544832 %)	Approved, Investigational	27742486
DrugRepV_2607	Linezolid	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6567659 %)	Approved, Investigational	27742486
DrugRepV_2609	Nevirapine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.6918978 %)	Approved	27742486
DrugRepV_2626	Voriconazole	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-1.8244532 %)	Approved	27742486
DrugRepV_2640	Levofloxacin	Antiinfectives For Systemic Use	Bacterial infections (Conjunctivitis)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.028788 %)	Approved, Investigational	27742486
DrugRepV_2645	Cidofovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.1015434 %)	Approved	27742486
DrugRepV_2653	Fluconazole	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.2384772 %)	Approved, Investigational	27742486
DrugRepV_2654	Trimethoprim	Antiinfectives For Systemic Use	Urinary tract infections | Uncomplicated pyelonephritis (with sulfamethoxazole) | Mild acute prostatitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.2572502 %)	Approved	27742486
DrugRepV_2667	Azlocillin Sodium salt	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4022354 %)	Approved	27742486
DrugRepV_2673	Cefprozil Hydrate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.4845708 %)	Approved	27742486
DrugRepV_2685	Oseltamivir phosphate	Antiinfectives For Systemic Use	Influenza A/B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.6044621 %)	Approved	27742486
DrugRepV_2689	Daptomycin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.764086 %)	Approved	27742486
DrugRepV_2693	Cloxacillin Sodium	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.8753795 %)	Approved	27742486
DrugRepV_2697	Fleroxacin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9243945 %)	Experimental	27742486
DrugRepV_2700	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-2.9691678 %)	Approved, Investigational	27742486
DrugRepV_2704	Sulbactam Sodium	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0092385 %)	Approved	27742486
DrugRepV_2706	Sulfadiazine	Antiinfectives For Systemic Use	Rheumatic fever | Meningococcal meningitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0259808 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2710	D-Cycloserine	Antiinfectives For Systemic Use	Antibiotic	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.0661555 %)	Approved	27742486
DrugRepV_2720	Tenofovir disoproxil Fumarate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.295385 %)	Approved, Investigational	27742486
DrugRepV_2721	Adefovir dipivoxil	Antiinfectives For Systemic Use	Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.3056399 %)	Approved	27742486
DrugRepV_2727	Ofloxacin	Antiinfectives For Systemic Use	Respiratory tract infections | Kidney infection | Skin infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4146475 %)	Approved	27742486
DrugRepV_2731	Rifabutin	Antiinfectives For Systemic Use	Mycobacterium avium complex (MAC) disease in patients with advanced Acquired immunodeficiency syndrome infection	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.4674544 %)	Approved, Investigational	27742486
DrugRepV_2734	Sulbactam	Antiinfectives For Systemic Use	Bacterial infections (Skin infection)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.5031618 %)	Approved	27742486
DrugRepV_2737	Didanosine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.5849038 %)	Approved	27742486
DrugRepV_2743	Oxytetracycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-3.6733944 %)	Approved, Investigational, Vet approved	27742486
DrugRepV_2764	Zalcitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.2270809 %)	Approved	27742486
DrugRepV_2775	Flucytosine	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4557163 %)	Approved, Investigational	27742486
DrugRepV_2777	Sulfamerazine	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.4815833 %)	Approved, Vet approved	27742486
DrugRepV_2783	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.5754617 %)	Approved	27742486
DrugRepV_2791	Abacavir Sulfate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.7456882 %)	Approved	27742486
DrugRepV_2795	Roxithromycin	Antiinfectives For Systemic Use	Respiratory tract | Urinary and soft tissue infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-4.8220241 %)	Approved	27742486
DrugRepV_2801	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.0142414 %)	Approved	27742486
DrugRepV_2833	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-5.947872 %)	Approved	27742486
DrugRepV_2839	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.2439742 %)	Approved	27742486
DrugRepV_2849	Amikacin Sulfate	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.6506378 %)	Approved	27742486
DrugRepV_2851	Sulfamethoxazole	Antiinfectives For Systemic Use	Bacterial infections (Bronchitis, prostatitis and urinary tract infections)	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-6.7837639 %)	Approved	27742486
DrugRepV_2886	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.4649195 %)	Approved, Investigational	27742486
DrugRepV_2892	Sparfloxacin	Antiinfectives For Systemic Use	Pneumonia | Acute bacterial exacerbations of chronic bronchitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-8.7240967 %)	Approved, Investigational, Withdrawn	27742486
DrugRepV_2901	Amoxicillin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.1354562 %)	Approved	27742486
DrugRepV_2902	Cefdinir	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.1747501 %)	Approved	27742486
DrugRepV_2911	Sulfanilamide	Antiinfectives For Systemic Use	Vulvovaginitis	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-9.7841731 %)	Approved	27742486
DrugRepV_2922	Amphotericin B	Antiinfectives For Systemic Use	Fungal infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-11.133117 %)	Approved	27742486
DrugRepV_2933	Erythromycin	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-14.433754 %)	Approved	27742486
DrugRepV_2934	Chloramphenicol	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	vAc-CHIKV 26S-Rhir-E	NA	Fusion index-Fluorescent Intensities	Increase (-14.926902 %)	Approved	27742486
DrugRepV_2952	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (2.76 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2953	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (1.50 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2954	Rolitetracycline	Antiinfectives For Systemic Use	Bacterial infection	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (3.76 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2955	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (0.96 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2956	Aciclovir	Antiinfectives For Systemic Use	Viral infection	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (2.30 ÌÑ 107 pfu/ml)	Approved	25970853
DrugRepV_2957	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	NA	NA	Approved	25970853
DrugRepV_2958	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	NA	NA	Approved	25970853
DrugRepV_2959	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	25970853
DrugRepV_2960	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved	25970853
DrugRepV_2962	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (51 %)	Approved	25970853
DrugRepV_2963	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Enzyme-linked immunosorbent assay	Decrease (68 %)	Approved	25970853
DrugRepV_2965	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (68 %)	Approved	25970853
DrugRepV_2966	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (45 %)	Approved	25970853
DrugRepV_2968	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (71 %)	Approved	25970853
DrugRepV_2969	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (44 %)	Approved	25970853
DrugRepV_2971	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (43 %)	Approved	25970853
DrugRepV_2972	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	Plaque assay	Decrease (67 %)	Approved	25970853
DrugRepV_2974	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (65 %)	Approved	25970853
DrugRepV_2975	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Clinical isolate of CHIKV (East/Central/South African genotype)	NA	MTT assay	Decrease (71.6 %)	Approved	25970853
DrugRepV_2982	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	CHIKV replicon	NA	EGFP assay	Decrease (50 %)	Approved	22205980
DrugRepV_2991	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	CHIKV replicon	NA	Rluc assay	Decrease (50 %)	Approved	22205980
DrugRepV_3051	Amphotericin B	Antiinfectives For Systemic Use	Fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (77 %)	Approved	26752081
DrugRepV_3060	Efavirenz	Antiinfectives For Systemic Use	Acquired immuno deficiency syndrome	Chikungunya virus	CHIKV-Rluc	NA	Luciferase reporter assay	Decrease (10 %)	Approved	26752081
DrugRepV_3062	Amphotericin B	Antiinfectives For Systemic Use	Fungal infection	Chikungunya virus	CHIKV-Rluc	NA	Renilla luciferase assay	No significant effect (90 %)	Approved	26752081
DrugRepV_3156	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	14670584
DrugRepV_3164	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (1.8 Log)	Approved	14670584
DrugRepV_3168	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Ross C347	NA	Cytopathic effect (CPE) assay	Decrease (99 %)	Approved	14670584
DrugRepV_3190	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Plaque assay	Decrease (50 %)	Approved, Investigational	22028179
DrugRepV_3193	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Plaque assay	No significant reduction (No significant reduction log)	Approved, Investigational	22028179
DrugRepV_3196	Rimantadine	Antiinfectives For Systemic Use	Influenza A virus	Influenza virus	A/Aichi/2/68		Quantal assay	Decrease (1 log)	Approved, Investigational	22028179
DrugRepV_3349	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	WSN/H1N1		Plaque assay	No significant effect (40 %)	Approved	29990517
DrugRepV_3351	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	WSN/H1N1		Plaque assay	Decrease (1.5 Log)	Approved	29990517
DrugRepV_3370	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Influenza virus	A/ WSN/1933 (H1N1)		High-throughput screening	Decrease (50 %)	Approved	24096239
DrugRepV_3377	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (50 %)	Approved	24096239
DrugRepV_3384	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (90 %)	Approved	24096239
DrugRepV_3390	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (99 %)	Approved	24096239
DrugRepV_3396	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	Real-time PCR	Decrease (>2 Log)	Approved	24096239
DrugRepV_3402	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	NA	NA	Plaque assay	Decrease (100 %)	Approved	24096239
DrugRepV_3410	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3411	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3412	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/07/2009 (H1N1)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3414	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3415	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	B/Bris/60/2008 (Victoria)		Plaque assay	Decrease (50 %)	Approved	28778830
DrugRepV_3418	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (1.7 Log)	Approved	28778830
DrugRepV_3419	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/California/7/2009 (H1N1)		Plaque assay	Decrease (2 Log)	Approved	28778830
DrugRepV_3421	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	A/WSN/1933 (H1N1)		Plaque assay	Decrease (1.4 Log)	Approved	28778830
DrugRepV_3550	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Chikungunya virus	Asian strain	NA	Real-time PCR	Decrease (50 %)	Approved	30455237
DrugRepV_3551	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Chikungunya virus	Asian strain	NA	Yield reduction assay	Decrease (50 %)	Approved	30455237
DrugRepV_3552	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Asian strain	NA	Real-time PCR	Decrease (50 %)	Approved	30455237
DrugRepV_3553	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	Asian strain	NA	Yield reduction assay	Decrease (50 %)	Approved	30455237
DrugRepV_3556	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Chikungunya virus	Asian strain	NA	Survival assay	Increase	Approved	30455237
DrugRepV_3557	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3558	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3559	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	181/clone 25	NA	Plaque assay	Decrease (50 %)	Approved	30354193
DrugRepV_3614	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Nipah virus	NA	NA	RT-PCR	Decrease	Approved	16641448
DrugRepV_3620	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Nipah virus	NA	NA	RT-PCR	Decrease	Approved	16641448
DrugRepV_3622	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Nipah virus	NA	NA	RT-PCR	Decrease	Approved	16641448
DrugRepV_3697	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	24713118
DrugRepV_3700	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	24713118
DrugRepV_3703	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	NA	NA	NA	Decrease (83 %)	Approved	24713118
DrugRepV_3707	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	NA	NA	NA	Decrease (0 %)	Approved	24713118
DrugRepV_3875	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3876	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3877	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Puerto Rican PRVABC-59	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3878	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3879	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Malaysian P 6-740	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3880	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3881	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_3882	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Ugandan MR-766	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	27838352
DrugRepV_4301	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Chikungunya virus	NA	NA	NA	Decrease (50 %)	Approved	27460167
DrugRepV_4310	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	Mayinga	NA	MTT assay	Decrease (50 %)	Approved	9988190
DrugRepV_4313	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	Sudan (Boneface strain)	NA	Plaque reduction assay	Decrease (50 %)	Approved	9988190
DrugRepV_4515	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4516	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4517	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Influenza virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_4529	Ganciclovir	Antiinfectives For Systemic Use	Cytomegalovirus infection	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved, Investigational	15200845
DrugRepV_4530	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease (100 %)	Approved	15200845
DrugRepV_4531	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4532	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4533	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved, Investigational	15200845
DrugRepV_4534	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4535	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4536	Oseltamivir	Antiinfectives For Systemic Use	Influenza A/B virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4537	Zanamivir	Antiinfectives For Systemic Use	Influenza virus	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4539	Foscarnet	Antiinfectives For Systemic Use	Cytomegalovirus retinitis | Herpesviruses | Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	CPE inhibition assay	Decrease	Approved	15200845
DrugRepV_4544	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	15961169
DrugRepV_4545	AZT	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	15961169
DrugRepV_4546	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Severe acute respiratory syndrome coronavirus	NA	NA	NA	Decrease (50 %)	Approved	15961169
DrugRepV_4614	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	v2163	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	19853271
DrugRepV_4615	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	Urbani	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	19853271
DrugRepV_4630	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Severe acute respiratory syndrome coronavirus	v2163	NA	Survival assay	No significant effect	Approved	19853271
DrugRepV_4648	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	28098253
DrugRepV_4649	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	Plaque assay	Decrease (50 %)	Approved	28098253
DrugRepV_4651	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (1.00E+02 pfu/ml)	Approved	28098253
DrugRepV_4652	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Plaque assay	Decrease (5.00E+07 pfu/ml)	Approved	28098253
DrugRepV_4688	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Approved	30061280
DrugRepV_4692	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Zika virus	NA	NA	Phenotypic assay	Decrease (50 %)	Approved	30061280
DrugRepV_4709	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	Immunoflourescence assay	Decrease	Approved	30061280
DrugRepV_4778	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Middle East respiratory syndrome coronavirus	Hu/Jordan-N3/2012	NA	Virus yield reduction assay	Decrease (30 %)	Approved	24323636
DrugRepV_4822	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4823	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4824	Dalbavancin	Antiinfectives For Systemic Use	Bacterial infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4825	Oritavancin	Antiinfectives For Systemic Use	Acute bacterial skin | Skin structure infections	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4826	Telavancin	Antiinfectives For Systemic Use	Skin infections (Bacterial)	Ebola virus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4829	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4830	Dalbavancin	Antiinfectives For Systemic Use	Bacterial infections	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4831	Oritavancin	Antiinfectives For Systemic Use	Acute bacterial skin | Skin structure infections	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_4832	Telavancin	Antiinfectives For Systemic Use	Skin infections (Bacterial)	Middle East respiratory syndrome coronavirus	NA	NA	Luciferase assay	Decrease (50 %)	Approved	26953343
DrugRepV_5078	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	10200	NA	Survival assay	No significant effect	Approved	29936152
DrugRepV_5079	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	Hoti	NA	Survival assay	No significant effect	Approved	29936152
DrugRepV_5080	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	10200	NA	Real-time PCR	Decrease	Approved	29936152
DrugRepV_5081	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	Hoti	NA	Real-time PCR	Decrease	Approved	29936152
DrugRepV_5082	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	NA	NA	Real-time PCR	Decrease (100 Copies/ml)	Approved	29584885
DrugRepV_5098	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	Decrease (50 %)	Approved	29024765
DrugRepV_5120	ABT-333	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (39 %)	Approved	29024765
DrugRepV_5125	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (24 %)	Approved	29024765
DrugRepV_5132	PSI-7977	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (4 %)	Approved	29024765
DrugRepV_5136	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (2 %)	Approved	29024765
DrugRepV_5137	Stavudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (26 %)	Approved, Investigational	29024765
DrugRepV_5139	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (0 %)	Approved, Investigational	29024765
DrugRepV_5140	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Crimean-Congo hemorrhagic fever virus	CCHFV/ZsG	NA	Fluorescence-based assay	No significant effect (27 %)	Approved	29024765
DrugRepV_5184	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	Approved	25144302
DrugRepV_5190	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	ZH501	NA	Immunoflourescence assay	Decrease (50 %)	Approved	25144302
DrugRepV_5196	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Ebola virus	Zaire	NA	Immunoflourescence assay	Decrease (50 %)	Approved	25144302
DrugRepV_5201	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Marburg virus	Ci67	NA	Immunoflourescence assay	Decrease (50 %)	Approved	25144302
DrugRepV_5205	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Lassa virus	Josiah	NA	Immunoflourescence assay	Decrease (50 %)	Approved	25144302
DrugRepV_5219	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Rift Valley fever virus	RVF-VLPs	NA	RLuc expression	Decrease (87.2 %)	Approved	21994655
DrugRepV_5225	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	IbAr 10200	NA	Neutral red uptake assay	Decrease (50 %)	Approved	15026198
DrugRepV_5230	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	Spu 128/81	NA	Neutral red uptake assay	Decrease (50 %)	Approved	15026198
DrugRepV_5235	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	Hy-13	NA	Neutral red uptake assay	Decrease (50 %)	Approved	15026198
DrugRepV_5240	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Crimean-Congo hemorrhagic fever virus	UG3010	NA	Neutral red uptake assay	Decrease (50 %)	Approved	15026198
DrugRepV_5252	Rifampicin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Variola virus	Butler	NA	Plaque assay	Decrease (Complete inhibition Plaque size)	Approved	4321450
DrugRepV_5475	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	SARS Coronavirus-2	nCoV- 2019BetaCoV/Wuhan/WIV04/2019	NA	qRT-PCR	Decrease (50 %)	Approved	32020029
DrugRepV_5524	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Lassa virus	NA	NA	Gaussia luciferase (Gluc) Glow assay	Decrease (50 %)	Approved	31786250
DrugRepV_5551	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5591	Chloramphenicol	Antiinfectives For Systemic Use	Bacterial infections	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5592	Tigecycline	Antiinfectives For Systemic Use	Complicated skin and skin structure infections	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved	32353859
DrugRepV_5593	Linezolid	Antiinfectives For Systemic Use	Bacterial infections	SARS Coronavirus-2	2019-nCoV/USA-WA1/2020	NA	NA	Decrease (50 %)	Approved, Investigational	32353859
DrugRepV_5628	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	16681		Enzyme-linked immunosorbent assay	Decrease (20 %)	Approved, Investigational	27396621
DrugRepV_5629	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	Hawaii		Enzyme-linked immunosorbent assay	Decrease (20 %)	Approved, Investigational	27396621
DrugRepV_5630	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	H87		Enzyme-linked immunosorbent assay	Decrease (30 %)	Approved, Investigational	27396621
DrugRepV_5631	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	H241		Enzyme-linked immunosorbent assay	Decrease (30 %)	Approved, Investigational	27396621
DrugRepV_5632	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	16681		Real-time PCR	Decrease (50 %)	Approved, Investigational	27396621
DrugRepV_5633	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Dengue virus	16681		Focus forming assay	Decrease (1 Log10 (FFU/ml))	Approved, Investigational	27396621
DrugRepV_5634	Lomefloxacin	Antiinfectives For Systemic Use	Bacterial infections (respiratory tract (chronic bronchitis) and urinary tract)	Dengue virus	16681		Enzyme-linked immunosorbent assay	No significant effect (5 %)	Approved, Investigational	27396621
DrugRepV_5635	Netilmicin	Antiinfectives For Systemic Use	Bacteremia | Septicaemia | Respiratory tract infections | Skin and soft-tissue infection | Burns | Wounds | Peri-operative infections caused by susceptible strains	Dengue virus	16681		Enzyme-linked immunosorbent assay	No significant effect (0 %)	Approved, Investigational	27396621
DrugRepV_5713	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	Approved	20973722
DrugRepV_5723	Acetylspiramycin	Antiinfectives For Systemic Use	Microbial infections	Dengue virus	New Guinea C		Fluorescence-based assay	Decrease (50 %)	NA	20973722
DrugRepV_5743	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Plaque assay	Decrease (50 %)	Approved	29297305
DrugRepV_5744	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Plaque assay	Decrease (50 %)	Phase III	29297305
DrugRepV_5745	Boceprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Real-time PCR	No significant effect	Phase II	29297305
DrugRepV_5746	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Real-time PCR	Decrease (2 Logs)	Approved	29297305
DrugRepV_5747	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	DV2-NGC		Real-time PCR	Decrease (5 Logs)	Phase III	29297305
DrugRepV_5752	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Dengue virus	DENV-2 replicon		Luciferase reporter assay	No significant effect (0 %)	NA	28814523
DrugRepV_5779	Clarithromycin	Antiinfectives For Systemic Use	NA	Dengue virus	Singapore isolates		Plaque assay	Decrease (72 %)	NA	25251726
DrugRepV_6128	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		NA	Decrease (50 %)	Approved	29890736
DrugRepV_6138	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C		DENV replicon assay	Decrease (50 %)	Approved	29672522
DrugRepV_6159	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	16681		MTT assay	Decrease (50 %)	Approved	22068705
DrugRepV_6168	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	02--20		Luciferase assay	Decrease (50 %)	Approved	24858611
DrugRepV_6178	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	ThNH-7/93		Fluorescent focus-forming assay	Decrease (50 %)	Approved	22784856
DrugRepV_6182	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C (NGC)		Cell proliferation assay	Decrease (50 %)	Approved	17662475
DrugRepV_6215	Tetracycline	Antiinfectives For Systemic Use	Bacterial infections (Rocky Mountain spotted fever | Typhus fever | Tick fevers | Q fever | Rickettsialpox | Brill-Zinsser disease)	Dengue virus	NA		Virus inhibition assay	Decrease (23.6 ± 2.1 %)	Approved	24522138
DrugRepV_6216	Oxytetracycline	Antiinfectives For Systemic Use	Bacterial infections	Dengue virus	NA		Virus inhibition assay	Decrease (18.8 ± 2.1 %)	Approved, Investigational, Vet approved	24522138
DrugRepV_6217	Doxycycline	Antiinfectives For Systemic Use	Bacterial infections	Dengue virus	NA		Virus inhibition assay	Decrease (50 %)	Approved	24522138
DrugRepV_6218	Rolitetracycline	Antiinfectives For Systemic Use	Bacterial infection	Dengue virus	NA		Virus inhibition assay	Decrease (32.8 ± 2.6 %)	Approved	24522138
DrugRepV_6219	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	NA		Virus inhibition assay	Decrease (50 %)	Approved	24522138
DrugRepV_6226	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	16681		Plaque assay	Decrease (1.75 * 105 pfu/ml)	Approved	7201778
DrugRepV_6348	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Dengue virus	New Guinea C (NGC)		NA	Decrease (50 %)	Approved	26856827
DrugRepV_6491	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Human immunodeficiency virus	NA		Modelling based approach	Decrease (50 %)	Approved	26796142
DrugRepV_6492	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		Modelling based approach	Decrease (50 %)	Approved	26796142
DrugRepV_6493	Tenofovir disoproxil Fumarate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		Modelling based approach	Decrease (50 %)	NA	26796142
DrugRepV_6501	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1ADA		Enzyme-linked immunosorbent assay	Decrease (50 %)	Approved, Investigational	15385252
DrugRepV_6502	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1ADA		Enzyme-linked immunosorbent assay	Decrease (71-96 %)	Approved, Investigational	15385252
DrugRepV_6503	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1ADA		Enzyme-linked immunosorbent assay	Decrease (85 %)	Approved, Investigational	15385252
DrugRepV_6504	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1BaL		Enzyme-linked immunosorbent assay	Decrease (65 %)	Approved, Investigational	15385252
DrugRepV_6505	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-189.6		Enzyme-linked immunosorbent assay	Decrease (NA %)	Approved, Investigational	15385252
DrugRepV_6506	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1JR-FL env		Luciferase reporter assay	Decrease (80 %)	Approved, Investigational	15385252
DrugRepV_6507	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1 VSV-G env		Luciferase reporter assay	Decrease (60 %)	Approved, Investigational	15385252
DrugRepV_6508	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1 AML-V env		Luciferase reporter assay	No significant effect (40 %)	Approved, Investigational	15385252
DrugRepV_6509	Minocycline	Antiinfectives For Systemic Use	Rocky Mountain spotted fever | Typhus fever and the typhus group | Q fever | Rickettsial pox | tick fevers caused by Rickettsiae | Upper respiratory tract infections caused by Streptococcus pneumoniae	Human immunodeficiency virus	HIV-1 VSV-G env		Luciferase reporter assay	Decrease (50 %)	Approved, Investigational	15385252
DrugRepV_6511	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6512	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6513	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		ECL RT biochemical assay	Decrease (50 %)	Approved	24379202
DrugRepV_6515	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6516	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6517	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		ECL RT biochemical assay	Decrease (50 %)	Approved	24379202
DrugRepV_6519	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6520	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		ECL RT biochemical assay	Decrease (50 %)	NA	24379202
DrugRepV_6521	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		ECL RT biochemical assay	Decrease (50 %)	Approved	24379202
DrugRepV_6523	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6524	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6525	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Wild type		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6527	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6528	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6529	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6531	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6532	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6533	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6535	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6536	Etravirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	NA	24379202
DrugRepV_6537	Rilpivirine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	K103N/Y181C		HIV multiple-cycle replication assay	Decrease (95 %)	Approved	24379202
DrugRepV_6568	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved, Investigational	20810732
DrugRepV_6569	Amprenavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6570	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6571	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6572	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved, Investigational	20810732
DrugRepV_6573	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6574	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6575	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved, Investigational	20810732
DrugRepV_6576	Darunavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	HIV-1ERS104pre		p24 assay	Decrease (50 %)	Approved	20810732
DrugRepV_6577	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6578	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6579	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6580	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6581	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6582	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6583	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6584	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6585	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6586	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6587	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6588	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6589	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6590	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6591	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6592	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6593	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6594	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6595	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6596	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6597	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6598	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6599	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6600	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6601	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6602	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6603	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6604	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6605	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6606	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6607	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6608	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6609	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6621	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	WT		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6622	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6623	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H(RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6624	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H (RAL)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6625	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T661(EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6626	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q (EVG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6627	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6628	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G118R (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6629	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6630	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	H51Y/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6631	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/R263K (DTG)		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6632	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6633	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6634	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6635	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6636	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6637	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6638	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6639	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6640	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6641	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6642	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6643	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6644	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6645	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6646	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6647	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6648	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6649	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6650	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6651	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6652	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6653	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6654	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6655	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6656	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6657	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6658	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6659	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6660	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6661	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6662	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6663	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6664	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6665	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6666	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6667	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6680	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	M50I		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6681	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6682	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6683	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S119R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6684	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6685	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6686	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146L		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6687	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q146P		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6688	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6689	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6690	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6691	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	S153Y		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6692	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6693	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6694	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6695	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6696	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6697	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6698	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6699	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6700	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6701	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6702	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6703	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6704	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6705	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6706	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6707	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6708	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6709	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6710	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6711	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6712	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6713	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6714	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6715	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6716	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6717	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6718	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6719	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6720	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6721	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6722	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6723	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6724	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6725	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6726	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6727	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6740	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6741	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6742	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6743	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6744	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6745	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6746	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6747	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6748	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6749	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6750	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6751	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Q148R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6752	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6753	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6754	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6755	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6756	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6757	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6758	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6759	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6760	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6761	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6762	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6763	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6764	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6765	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6766	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6767	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6768	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6769	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6776	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6777	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6778	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6779	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6780	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6781	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6782	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6783	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6784	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6785	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6786	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6787	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6788	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6789	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6790	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6791	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6792	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6793	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6794	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6795	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6796	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6797	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6798	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6799	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6800	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6801	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6802	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6810	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	97A/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6811	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6812	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140A/Q148K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6813	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140A/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6814	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	L74M/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6815	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140C/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6816	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/S147G/Q148R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6817	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6818	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6819	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6820	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6821	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6822	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6823	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6824	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6825	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6826	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6827	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6828	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6833	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T66I/T97A/E157Q		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6834	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6835	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6836	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E92Q/N155H/G163R		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6837	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6838	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6839	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6840	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6841	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6842	Raltegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6843	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6844	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6845	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6846	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6847	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6848	Elvitegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6849	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6850	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6851	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6852	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6853	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6854	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6861	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	T97A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6862	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138A/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6863	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	E138K/G140S/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6864	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Y143R/Q148H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6865	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/N155H		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6866	Bictegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	G140S/Q148H/G163K		Single-round viral replication assay	Decrease (50 %)	Approved	29769116
DrugRepV_6926	AzidoThymidine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	IIIB		MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6956	AzidoThymidine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	ROD		MTT assay	Decrease (50 %)	Approved	25970561
DrugRepV_6958	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_6959	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_6960	Zidovudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome/AIDS	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_6961	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved, Investigational	15200845
DrugRepV_6962	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		NA	Decrease (95 %)	Approved	15200845
DrugRepV_6963	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Human immunodeficiency virus	NA		NA	Decrease (50 %)	Approved	15200845
DrugRepV_7011	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (50 %)	NA	28814523
DrugRepV_7020	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Plaque assay	Decrease (3 Logs)	NA	28814523
DrugRepV_7025	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Real-time PCR	Decrease (0.1 %)	NA	28814523
DrugRepV_7030	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Immunoflourescence assay	Decrease (100 %)	NA	28814523
DrugRepV_7035	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (70 %)	NA	28814523
DrugRepV_7040	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Japanese encephalitis virus	AT31		Luciferase reporter assay	Decrease (100 %)	NA	28814523
DrugRepV_7045	Nelfinavir Mesylate	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	WNV replicon		Luciferase reporter assay	Decrease (72 %)	NA	28814523
DrugRepV_7089	Teicoplanin	Antiinfectives For Systemic Use	Bacterial infections	Polio virus	Sabin		Plaque assay	No significant effect	Approved	26585243
DrugRepV_7447	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7448	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	Uganda strain B 956		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7459	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		NR assay	Decrease (50 %)	Approved	12076755
DrugRepV_7460	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	Uganda strain B 956		NR assay	Decrease (50 %)	Approved	12076755
DrugRepV_7506	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		Visual assay	Decrease (50 %)	Approved	12076755
DrugRepV_7511	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	New York		Virus yield reduction assay	Decrease (90 %)	Approved	12076755
DrugRepV_7519	Rifampicin	Antiinfectives For Systemic Use	Tuberculosis and Tuberculosis-related mycobacterial infections	Vaccinia virus	NA		Plaque assay	Decrease (Complete inhibition Plaque size)	Approved	4321450
DrugRepV_7525	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7526	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/MO/14-18949		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7527	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/MO/14-18947		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7528	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/IL/14-18952		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7529	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/IL/14-18956		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7530	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7531	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7532	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7533	Telaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Enterovirus	US/KY/14-18953		Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	30674624
DrugRepV_7550	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7551	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7560	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	Brazil/RJ-314/2020	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7561	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	Brazil/RJ-314/2020	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7562	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7563	Azithromycin	Antiinfectives For Systemic Use	Microbial infections	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7568	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7602	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7603	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7620	Umifenovir	Antiinfectives For Systemic Use	Prophylaxis/treatment of influenza in Russia and China	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (50 %)	Investigational	32438446
DrugRepV_7621	Umifenovir	Antiinfectives For Systemic Use	Prophylaxis/treatment of influenza in Russia and China	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (90 %)	Investigational	32438446
DrugRepV_7622	Anidulafungin	Antiinfectives For Systemic Use	Invasive candidiasis/candidaemia	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Immunofluorescence	Decrease (50 %)	Approved, Investigational	32438446
DrugRepV_7623	Anidulafungin	Antiinfectives For Systemic Use	Invasive candidiasis/candidaemia	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Immunofluorescence	Decrease (90 %)	Approved, Investigational	32438446
DrugRepV_7625	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020	NA	Immunofluorescence	Decrease (50 %)	Approved	32438446
DrugRepV_7626	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020	NA	Immunofluorescence	Decrease (90 %)	Approved	32438446
DrugRepV_7629	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved, Investigational	32438446
DrugRepV_7630	Saquinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved, Investigational	32438446
DrugRepV_7633	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved, Investigational	32438446
DrugRepV_7634	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved, Investigational	32438446
DrugRepV_7635	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7636	Atazanavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7643	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved, Investigational	32438446
DrugRepV_7644	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved, Investigational	32438446
DrugRepV_7645	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7646	Dolutegravir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	BavPat1	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7647	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32438446
DrugRepV_7648	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	?CoV/KOR/KCDC03/2020)	NA	Cytopathic effect (CPE) assay	Decrease (90 %)	Approved	32438446
DrugRepV_7652	Amprenavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7653	Amprenavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7655	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Approved	32438446
DrugRepV_7656	Penciclovir	Antiinfectives For Systemic Use	Recurrent cold sores on the lips and face from Herpesvirus invections	SARS Coronavirus-2	Wuhan/WIV04/2019	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Approved	32438446
DrugRepV_7657	Darunavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7658	Darunavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7659	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (50 %)	Approved	32438446
DrugRepV_7660	Ribavirin	Antiinfectives For Systemic Use	Hepatitis C virus	SARS Coronavirus-2	Wuhan/WIV04/2022	NA	qRT-PCR/ NP expression/Immunofluorescence	Decrease (90 %)	Approved	32438446
DrugRepV_7661	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (50 %)	Approved	32438446
DrugRepV_7662	Indinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	RT-PCR	Decrease (90 %)	Approved	32438446
DrugRepV_7680	Clofazamine	Antiinfectives For Systemic Use	Lepromatous leprosy	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7682	Entecavir	Antiinfectives For Systemic Use	Hepatitis B virus	SARS Coronavirus-2		NA	NA	Decrease (50 %)	Approved	32577649
DrugRepV_7708	Lopinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2		NA	Plaque reduction assay	Decrease (50 %)	Approved	32532085
DrugRepV_7712	Clofazimine	Antiinfectives For Systemic Use	Lepromatous leprosy	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Approved	32707573
DrugRepV_7726	Clofazimine	Antiinfectives For Systemic Use	Lepromatous leprosy	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Approved	32707573
DrugRepV_7754	Clofazimine	Antiinfectives For Systemic Use	Lepromatous leprosy	SARS Coronavirus-2	SARS-CoV-2-USA-WA1/2020	NA	Immunofluorescence	Decrease (50 %)	Approved	32707573
DrugRepV_7774	Ritonavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	NA	Decrease (50 %)	Approved, Investigational	32687696
DrugRepV_8144	Idoxuridine	Antiinfectives For Systemic Use	Keratoconjunctivitis and Keratitis caused by herpes simplex virus	Vaccinia virus	NA		NA	Decrease (85.8 %)	Approved, Investigational	32708182
DrugRepV_8167	Adefovir dipivoxil	Antiinfectives For Systemic Use	Hepatitis B virus	Vaccinia virus	NA		NA	Decrease (99.8 %)	Approved	32708182
DrugRepV_8193	AT13387	Antiinfectives For Systemic Use	Hepatitis C virus	Vaccinia virus	NA		NA	Decrease (99.8 %)	Phase III	32708182
DrugRepV_8277	Asunaprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Phase III	32488021
DrugRepV_8278	Simeprevir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	NA	NA	MTT assay	Decrease (50 %)	Approved	32488021
DrugRepV_8299	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8300	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8301	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8302	Efavirenz	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	13-104		Plaque assay	Decrease (50 %)	NA	32326119
DrugRepV_8303	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8304	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8305	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8306	Tipranavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	West Nile virus	13-104		Plaque assay	Decrease (50 %)	Approved, Investigational	32326119
DrugRepV_8307	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	Paraiba_01	NA	Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8308	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	Zika virus	MR-766	NA	Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8309	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	Eg101		Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8310	Dasabuvir	Antiinfectives For Systemic Use	Hepatitis C virus	West Nile virus	13-104		Plaque assay	Decrease (50 %)	Approved	32326119
DrugRepV_8326	Tenofovir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved, Investigational	32429580
DrugRepV_8330	Lamivudine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome | Hepatitis B virus	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32429580
DrugRepV_8332	Emtricitabine	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	Experimental	NA	Cytopathic effect (CPE) assay	Decrease (50 %)	Approved	32429580
DrugRepV_8338	Nelfinavir	Antiinfectives For Systemic Use	Acquired immunodeficiency syndrome	SARS Coronavirus-2	NA	NA	NA	Decrease (100 %)	Approved	32374457
DrugRepV_8451	Sofosbuvir	Antiinfectives For Systemic Use	Hepatitis C virus | Acquired immunodeficiency syndrome	Yellow fever virus	YFV17D		NA	Decrease (50 %)	Approved	30699122
DrugRepV_8452	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Influenza virus	PR8M		MTT assay	Decrease (50 %)	Approved, Investigational	30866762
DrugRepV_8453	Itraconazole	Antiinfectives For Systemic Use	Fungal infections (Pulmonary and extrapulmonary blastomycosis, Histoplasmosis, Aspergillosis, and Onychomycosis)	Influenza virus	PR8M		MTT assay	Decrease (90 %)	Approved, Investigational	30866762
DrugRepV_8454	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Influenza virus	PR8M		MTT assay	Decrease (50 %)	Approved, Investigational, Vet approved	30866762
DrugRepV_8455	Posaconazole	Antiinfectives For Systemic Use	Fungal infections (Aspergillus and Candida infections)	Influenza virus	PR8M		MTT assay	Decrease (90 %)	Approved, Investigational, Vet approved	30866762